IL6 and congenital rubella syndrome: Cardio- myopathy, complement activation, coagulation cascade activation and hyperinflammation-like disseminated intravascular coagulation develop because of IL-6 release.18 Tocilizumab reduces the harmful effects of hyperinflammation by decreasing IL-6 signal transmission in cases of severe CRS.19 Therefore, patients diagnosed with COVID-19 should be followed up regarding hyperinflammation.20